Actively Recruiting
Study of Long-term Transcutaneous Auricular Vagus Nerve Stimulation as a Treatment for Early Parkinsons Disease in Adults 55 to 75 Years
Led by Kezhong Zhang · Updated on 2025-01-14
12
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the effects of long-term transcutaneous auricular vagus nerve stimulation taVNS in patients with early-stage Parkinsons disease. This randomized, double-blind, controlled trial aims to explore a new treatment approach to potentially delay the progression of Parkinsons disease in adults aged 55 to 75 years who have been diagnosed based on specific clinical criteria and have mild disease severity. Participants receive either real or sham taVNS stimulation alongside their standard anti-Parkinsons medication. For the real stimulation group, electrodes deliver pulses near the auricular branch of the vagus nerve in the left ear for a 30-minute session each day, at least five days per week, over 270 consecutive days. The sham group receives stimulation on the earlobes with the same schedule and device settings to serve as a comparison. Throughout the study, participants undergo regular assessments using motor function scales like MDS-UPDRS and imaging techniques such as diffusion tensor imaging to measure changes in brain structures. Evaluations occur at baseline and multiple follow-up points up to approximately 570 days. Researchers monitor symptoms, movement parameters, and disease stage while ensuring participant safety and adherence to the treatment and follow-up schedule.
CONDITIONS
Brief Title
Neuroprotective Effects of Long-term TaVNS in Early Parkinson's Disease Patients
Research Team
K
Kezhong Zhang, Professor
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here